Opaleye Management
Latest statistics and disclosures from Opaleye Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are HROW, ETON, LQDA, RYTM, IMNM, and represent 55.66% of Opaleye Management's stock portfolio.
- Added to shares of these 10 stocks: APGE (+$14M), ALKS (+$14M), ANNX (+$7.9M), DERM (+$6.2M), SLGL (+$6.0M), CGON (+$5.8M), PLX (+$5.7M), TMCI, LQDA, STOK.
- Started 11 new stock positions in APGE, SYRE, PLX, TMCI, ALKS, ACOG, CABA, ANNX, ADCT, RIGL. SLGL.
- Reduced shares in these 10 stocks: VIGL (-$8.0M), ANIK (-$6.2M), Gossamer Bio (-$5.9M), ARVN (-$5.9M), DNA (-$5.6M), IMNM, EPIX, CRGX, TARA, ZNTL.
- Sold out of its positions in ANIK, RCEL, CRGX, ELEV, EPIX, DNA, Gossamer Bio, TARA, VIGL.
- Opaleye Management was a net buyer of stock by $23M.
- Opaleye Management has $707M in assets under management (AUM), dropping by 43.14%.
- Central Index Key (CIK): 0001595855
Tip: Access up to 7 years of quarterly data
Positions held by Opaleye Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Opaleye Management
Opaleye Management holds 43 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Harrow Health (HROW) | 26.6 | $188M | 3.9M | 48.18 |
|
|
| Eton Pharmaceuticals (ETON) | 8.8 | $62M | 2.9M | 21.73 |
|
|
| Liquidia Corporation Com New (LQDA) | 8.4 | $60M | +5% | 2.6M | 22.74 |
|
| Rhythm Pharmaceuticals (RYTM) | 6.6 | $47M | -2% | 462k | 100.99 |
|
| Immunome (IMNM) | 5.3 | $37M | -9% | 3.2M | 11.71 |
|
| Sanuwave Health (SNWV) | 5.2 | $37M | 980k | 37.48 |
|
|
| Codexis (CDXS) | 4.4 | $31M | 13M | 2.44 |
|
|
| Tg Therapeutics (TGTX) | 2.7 | $19M | 535k | 36.12 |
|
|
| Ocular Therapeutix (OCUL) | 2.6 | $19M | 1.6M | 11.69 |
|
|
| Cg Oncology (CGON) | 2.3 | $17M | +54% | 410k | 40.28 |
|
| Stoke Therapeutics (STOK) | 2.3 | $16M | +21% | 682k | 23.50 |
|
| Apogee Therapeutics (APGE) | 2.0 | $14M | NEW | 363k | 39.73 |
|
| Alkermes SHS (ALKS) | 1.9 | $14M | NEW | 450k | 30.00 |
|
| Disc Medicine (IRON) | 1.8 | $13M | +3% | 194k | 66.08 |
|
| Sarepta Therapeutics (SRPT) | 1.6 | $11M | +17% | 585k | 19.27 |
|
| Larimar Therapeutics (LRMR) | 1.5 | $11M | -9% | 3.7M | 2.84 |
|
| Xoma Corp Del Com New (XOMA) | 1.4 | $9.8M | 255k | 38.54 |
|
|
| Rezolute Com New (RZLT) | 1.2 | $8.5M | 903k | 9.40 |
|
|
| Arvinas Ord (ARVN) | 1.2 | $8.4M | -41% | 988k | 8.52 |
|
| Edgewise Therapeutics (EWTX) | 1.1 | $8.1M | +2% | 500k | 16.22 |
|
| Annexon (ANNX) | 1.1 | $7.9M | NEW | 2.6M | 3.05 |
|
| Gossamer Bio (GOSS) | 1.0 | $7.2M | -23% | 2.7M | 2.63 |
|
| Protagonist Therapeutics (PTGX) | 1.0 | $7.0M | 105k | 66.43 |
|
|
| Journey Med Corp (DERM) | 1.0 | $6.9M | +922% | 971k | 7.12 |
|
| Sol Gel Technologies Shs New (SLGL) | 0.8 | $6.0M | NEW | 205k | 29.15 |
|
| Protalix Biotherapeutics (PLX) | 0.8 | $5.7M | NEW | 2.6M | 2.22 |
|
| Treace Med Concepts (TMCI) | 0.7 | $4.7M | NEW | 702k | 6.71 |
|
| Revolution Medicines (RVMD) | 0.7 | $4.7M | -4% | 100k | 46.70 |
|
| Karyopharm Therapeutics Note 3.000%10/1 (Principal) | 0.7 | $4.6M | 6.0M | 0.77 |
|
|
| Mbx Biosciences (MBX) | 0.6 | $4.4M | +5% | 253k | 17.50 |
|
| Trevi Therapeutics (TRVI) | 0.5 | $3.6M | 390k | 9.15 |
|
|
| ADC Therapeutics SA SHS (ADCT) | 0.4 | $2.7M | NEW | 683k | 4.00 |
|
| Alumis (ALMS) | 0.4 | $2.7M | -14% | 665k | 3.99 |
|
| Cabaletta Bio (CABA) | 0.3 | $1.9M | NEW | 809k | 2.34 |
|
| Ocuphire Pharma (IRD) | 0.3 | $1.8M | -9% | 1.1M | 1.65 |
|
| Zymeworks Del (ZYME) | 0.2 | $1.7M | -52% | 100k | 17.08 |
|
| Spyre Therapeutics Com New (SYRE) | 0.2 | $1.1M | NEW | 65k | 16.76 |
|
| Rigel Pharmaceuticals (RIGL) | 0.2 | $1.1M | NEW | 38k | 28.33 |
|
| Alpha Cognition Com New (ACOG) | 0.1 | $750k | NEW | 115k | 6.51 |
|
| Zentalis Pharmaceuticals (ZNTL) | 0.1 | $478k | -83% | 317k | 1.51 |
|
| Pepgen (PEPG) | 0.0 | $347k | -68% | 75k | 4.62 |
|
| Ibio Com New (IBIO) | 0.0 | $310k | 375k | 0.83 |
|
|
| Adagio Med Hldgs (ADGM) | 0.0 | $215k | 111k | 1.94 |
|
Past Filings by Opaleye Management
SEC 13F filings are viewable for Opaleye Management going back to 2013
- Opaleye Management 2025 Q3 filed Nov. 14, 2025
- Opaleye Management 2025 Q2 restated filed Aug. 15, 2025
- Opaleye Management 2025 Q1 filed May 15, 2025
- Opaleye Management 2024 Q4 filed Feb. 14, 2025
- Opaleye Management 2024 Q3 filed Nov. 14, 2024
- Opaleye Management 2024 Q2 filed Aug. 14, 2024
- Opaleye Management 2024 Q1 restated filed May 29, 2024
- Opaleye Management 2024 Q1 filed May 15, 2024
- Opaleye Management 2023 Q4 filed Feb. 14, 2024
- Opaleye Management 2023 Q3 filed Nov. 15, 2023
- Opaleye Management 2023 Q2 filed Aug. 14, 2023
- Opaleye Management 2023 Q1 filed May 15, 2023
- Opaleye Management 2022 Q4 filed Feb. 10, 2023
- Opaleye Management 2022 Q3 filed Nov. 14, 2022
- Opaleye Management 2022 Q2 filed Aug. 15, 2022
- Opaleye Management 2022 Q1 filed May 16, 2022